What eGFR and creatinine actually mean when they show up on a blood test
Creatinine is muscle waste your kidneys clear; eGFR is an estimate of filtering capacity built from it. A single reading is a snapshot, not a diagnosis — and the equations have limits worth knowing.
When a blood test comes back with a creatinine value and an eGFR, the two numbers are measuring the same thing from opposite ends: creatinine is a waste product your kidneys are supposed to clear, and eGFR is an estimate of how well they are clearing it [s1]. Neither number alone is a diagnosis, and understanding what each actually represents is the difference between a useful conversation with a clinician and an unnecessary scare.
What creatinine is
Creatinine is a waste product from the normal breakdown of muscle in your body, and healthy kidneys remove it from the blood [s1]. Because production is relatively steady but clearance depends on kidney function, the amount left circulating is a usable proxy: as kidney disease progresses and filtering slows, the creatinine level in the blood goes up [s1]. That also explains one of creatinine's quirks — it reflects muscle as well as kidneys, which is part of why the raw number is converted into an estimate that accounts for other factors rather than read on its own.
What eGFR is, and what the ranges mean
GFR stands for glomerular filtration rate — the rate at which the kidneys filter blood [s1]. The "e" is the honest part: it is an estimated rate, calculated from the blood creatinine level using an equation, not a direct measurement [s3]. Providers use it as the key marker for chronic kidney disease [s3].
The NIH's kidney institute gives the plain-language bands: a GFR of 60 or more is in the normal range; a GFR below 60 may indicate kidney disease; and a GFR of 15 or less is classed as kidney failure, the point at which most people need dialysis or a transplant [s1]. One blunt but important line from the same source: you cannot raise your GFR, but the goal of treatment is to keep it from falling further [s1].
Crucially, eGFR is rarely interpreted alone. The kidney institute pairs it with a urine test for albumin, a protein that a healthy kidney keeps out of the urine but a damaged one lets through [s1]. A urine albumin-to-creatinine ratio above 30 mg/g may be a sign of kidney disease, and providers often repeat the test to confirm it [s1]. Two people with the same eGFR but different albumin levels do not have the same kidney picture.
The repeat-testing point is not a formality. Because a single value is a snapshot and can be nudged by short-term factors, one abnormal result is a prompt to recheck rather than a diagnosis — the NIH institute notes that providers may repeat the urine test one or two more times to confirm a result before acting on it [s1]. And because creatinine reflects muscle as well as kidney function, a second blood marker, cystatin C, is sometimes used alongside it; the race-free equations that combine creatinine with cystatin C were the most accurate versions in the 2021 study [s2]. None of this is something a reader can adjudicate from the lab printout alone.
The limits built into the estimate
The equation is imperfect by design. The kidney institute notes that eGFR is calculated using estimating equations that may not always be precise, and that most of these equations become less accurate as GFR increases — meaning the number is at its shakiest in the near-normal range where a lot of anxious readers land [s3]. A single value can also be nudged by things unrelated to long-term kidney health, which is why one reading is a snapshot, not a trend.
The equations themselves have also changed. Older eGFR formulas included a race coefficient. A 2021 study in the New England Journal of Medicine developed and validated new equations that omit race, on the stated basis that race is a social rather than a biological construct [s2]. Those race-free equations, especially versions that combine creatinine with a second marker called cystatin C, were found to be accurate enough that 85% or more of estimates fell within 30% of a directly measured GFR — a reminder that even the improved equations carry a real margin of error around any single figure [s2].
What this leaves a reader with
An eGFR below 60 or albumin in the urine is a reason to talk with a clinician, not a self-diagnosis — the numbers need repeating, pairing with each other, and interpreting against a person's age, muscle mass and medical history [s1]. What the tests do well is catch kidney disease early, when it usually causes no symptoms at all; what they do not do is deliver a verdict from one line on a lab report [s1] [s3].
This article is informational and is not medical advice.
Sources
- Chronic Kidney Disease (CKD) Tests & Diagnosis — National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race — New England Journal of Medicine, 2021-09-23
- Estimated Glomerular Filtration Rate Calculators — National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
Sources
- Chronic Kidney Disease (CKD) Tests & Diagnosis — National Institute of Diabetes and Digestive and Kidney Diseases (NIH) , January 1, 2024
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race — New England Journal of Medicine , September 23, 2021
- Estimated Glomerular Filtration Rate Calculators — National Institute of Diabetes and Digestive and Kidney Diseases (NIH) , January 1, 2024
More on
In kidney disease, cutting salt lowers blood pressure and protein leak into urine
In people who already have kidney disease, cutting salt reduced albuminuria by about 36% and lowered blood pressure. High salt also blunts standard kidney-protecting drugs — though long-term outcome trials are missing.
Protecting your kidneys is mostly about two conditions you cannot feel
Kidney disease is usually silent until it is advanced, and most of it traces to diabetes and high blood pressure. Controlling those two, and getting tested, is the highest-yield protection — not kidney superfoods.
SGLT2 drugs slow kidney disease and cut heart events — with or without diabetes
A meta-analysis of 90,000 people found these diabetes-origin drugs reduced kidney disease progression by 37% and cardiovascular events by 23%, and the benefit was similar in people who did not have diabetes.
Lowering high uric acid did not protect the kidneys in two randomised trials
High urate levels track with worsening kidney disease, so treating them seemed a logical way to slow it. Two trials that lowered urate with allopurinol found the kidneys declined at the same rate anyway.